Desentum
Desentum is developing a new immunotherapy for the treatment of allergies – an allergy vaccine.
Funding rounds
10/2017, 9/2019, 1/2022, 1/2024, 3/2026, 4/2026
Valuation after latest round
€120.2 million
Springvest's ownership stake
7.2% (30 June 2026)
Sector
Life sciences
